DRG Epidemiology’s coverage of hepatocellular carcinoma comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of hepatocellular carcinoma for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report. In addition to forecasting incident and prevalent patient populations, we estimate the number of drug-treatment opportunities in specific lines of therapy.

DRG Epidemiology’s hepatocellular carcinoma forecast will answer the following questions:

  • How will changes in the levels of exposure to known risk or protective factors affect the number of people diagnosed with hepatocellular carcinoma each year?
  • In developing countries, what impact will economic growth and development have on the number of people diagnosed with hepatocellular carcinoma each year?
  • How will improvements in survival change the number of people living with a diagnosis of hepatocellular carcinoma?
  • How will a declining risk of recurrence change the number of people diagnosed with hepatocellular carcinoma each year?
  • Of all people with hepatocellular carcinoma, how many in each of the major mature pharmaceutical markets have been formally diagnosed?
  • Of all people diagnosed with hepatocellular carcinoma, how many in each of the major mature pharmaceutical markets are drug-treated?

All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is provided for full transparency into research and methods. In addition, we provide a graph of the patient flow between or within different disease states for the countries considered in this report. These patient-flow diagrams are provided at the regional level but may be requested for any specific country or forecast year.

DRG Epidemiology provides at least ten years of forecast data for the following hepatocellular carcinoma patient populations:

  • Diagnosed incident cases of hepatocellular carcinoma.
  • Diagnosed incident cases by stage distribution.
  • Diagnosed prevalent cases of hepatocellular carcinoma.
  • Diagnosed prevalent cases by metastasis status.
  • Advanced first-line drug-treatable hepatocellular carcinoma population.
  • Advanced second-line drug-treatable population by treatment.
  • Intermediate drug-treatable hepatocellular carcinoma population.
  • Early drug-treatable hepatocellular carcinoma population.

… and more (details available on request).

Note: Coverage may vary by country and region.

Table of contents

  • Hepatocellular Carcinoma - Epidemiology - Emerging Markets Data
    • Introduction
      • Key Findings
        • Overview
          • Incidence of Hepatocellular Carcinoma per Year per 100,000 People of All Ages in 2019 and 2029
          • Depiction of the Patient Flow in Hepatocellular Carcinoma in the Emerging Markets, 2019
          • Relative Sizes of the Factors Contributing to the Trend in Incident Cases of Hepatocellular Carcinoma over the Next Ten Years
          • Number of Incident Cases of Hepatocellular Carcinoma Avoided over 2019-2029 in the Countries Under Study
          • Diagnosed Incident Cases of Hepatocellular Carcinoma in the Countries Under Study by Stage
      • Methods
        • Newly Diagnosed Incidence
        • Stage Distribution
        • Recurrent Incidence
        • Diagnosed Prevalence
        • Drug-Treatable and Drug-Treated Populations
        • Lifetime DALYs Gained
      • Epidemiology Data
      • Reference Materials
        • Literature Review
          • Studies Included in the Analysis of Hepatocellular Carcinoma
          • Studies Excluded from the Analysis of Hepatocellular Carcinoma
        • Risk/Protective Factors
          • Risk/Protective Factors for Hepatocellular Carcinoma
        • Bibliography

      Author(s): Oliver Blandy, M.Sc.

      Oliver Blandy, M.Sc., is a senior epidemiologist at DRG, part of Clarivate. Before joining DRG, Oliver worked as a research assistant for Imperial College London, where he was the lead for several studies within an NIRH-funded research group investigating healthcare-associated infections and antimicrobial resistance. He holds an M.Sc. from the University of Bristol, where he specialized in nutrition, physical activity, and public health. He also holds a B.Sc. in chemistry and a postgraduate certificate in education, both from the University of Bristol.


      Related Reports

      Hepatocellular Carcinoma - Landscape & Forecast - Disease Landscape & Forecast

      Hepatocellular carcinoma is a primary malignancy of the liver that commonly arises from liver cirrhosis. Nexavar (Bayer HealthCare / Amgen / Onyx) was the only drug approved for advanced disease un...

      View Details

      Hepatocellular Carcinoma | Disease Landscape and Forecast | G7 | 2020

      Hepatocellular carcinoma is a primary malignancy of the liver that commonly arises from liver cirrhosis. Nexavar (Bayer HealthCare / Amgen / Onyx) was the only drug approved for advanced disease un...

      View Details

      Hepatocellular Carcinoma - Geographic Focus: China - Hepatocellular Carcinoma - China In-Depth (China)

      MARKET OUTLOOK The hepatocellular carcinoma (HCC) market in China is poised to experience substantial market growth. Availability of systemic targeted drugs is limited, with...

      View Details

      Hepatocellular Carcinoma - Unmet Need - Detailed, Expanded Analysis - Advanced Hepatocellular Carcinoma (US/EU5)

      Hepatocellular carcinoma, the most common type of primary liver cancer, occurs as a results of chronic liver cirrhosis and has a five-year survival rate of only 18%. First-line advanced hepatocellu...

      View Details